John A. Josey
Director/Board Member at DAY ONE BIOPHARMACEUTICALS, INC.
Net worth: 1 M $ as of 2024-03-30
Profile
John A.
Josey's current jobs include being the Chairman at Circle Pharma, Inc., Chairman at Atavistik Bio, Inc., Director at VHL Alliance, Independent Director at Day One Biopharmaceuticals, Inc., Venture Partner at The Column Group LLC, and Chief Executive & Financial Officer, SEC, BRD at Nura Bio, Inc. Dr. Josey's former jobs include being the President, Chief Executive Officer & Director at Peloton Therapeutics, Inc., Principal at Glaxo, Inc., Principal at Amgen, Inc., and Vice President-Discovery Chemistry at Array BioPharma, Inc. Dr. Josey's education history includes an undergraduate degree from Colorado State University, an MBA from The University of Colorado, and a doctorate from The University of Texas at Austin.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-06-21 | 72,292 ( 0.08% ) | 1 M $ | 2024-03-30 |
John A. Josey active positions
| Companies | Position | Start |
|---|---|---|
| DAY ONE BIOPHARMACEUTICALS, INC. | Director/Board Member | 2020-08-31 |
Circle Pharma, Inc.
 Circle Pharma, Inc. BiotechnologyHealth Technology Circle Pharma, Inc. provides biotechnology services. The company was founded by Matthew P. Jacobson and Scott Lokey in June 2014 and is headquartered in San Francisco, CA. | Chairman | 2020-03-19 |
Atavistik Bio, Inc.
 Atavistik Bio, Inc. BiotechnologyHealth Technology Atavistik Bio, Inc. is a pre-clinical stage biotechnology company located in an undisclosed location. The American company is pioneering a synthetic, scalable approach to identify and harness highly conserved protein-metabolite interactions to revolutionize small molecule drug discovery. The company's advanced data analytics and AI platforms leverage structure-based drug design to engineer novel, highly specific small molecule drugs to activate, inhibit or stabilize targets. The company is led by an experienced management team and advisors, plus a robust investment syndicate, and is positioned to deliver transformational science to ultimately improve patient care. Atavistik Bio was founded by prominent scientists who are considered among the leading authorities in cell biology, cancer cell biology and cell metabolism. Bryan E Stuart has been the CEO of the company since 2023. | Chairman | 2021-12-31 |
The Column Group LLC
 The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Private Equity Investor | 2020-02-29 |
Nura Bio, Inc.
 Nura Bio, Inc. Pharmaceuticals: MajorHealth Technology Nura Bio, Inc. develops neuroprotective drugs. The company is headquartered in South San Francisco, CA. | Chief Executive Officer | - |
| VHL Alliance | Director/Board Member | - |
Former positions of John A. Josey
| Companies | Position | End |
|---|---|---|
| PELOTON THERAPEUTICS, INC. | Chief Executive Officer | 2019-07-30 |
| ARRAY TECHNOLOGIES, INC. | Corporate Officer/Principal | 2011-08-29 |
| AMGEN INC. | Corporate Officer/Principal | 1998-12-30 |
| ░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of John A. Josey
| Colorado State University | Undergraduate Degree |
| The University of Texas at Austin | Doctorate Degree |
| The University of Colorado | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| DAY ONE BIOPHARMACEUTICALS, INC. | Health Technology |
| Private companies | 8 |
|---|---|
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
Peloton Therapeutics, Inc.
 Peloton Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in translating novel scientific insights into medicines for patients with cancer and other debilitating or life-threatening conditions. Its lead drug candidate is a small molecule which targets HIF-2a, a transcription factor implicated in the development and progression of renal and other cancers. The company was founded by Steven L. McKnight in August 2010 and is headquartered in Dallas, TX. | Health Technology |
The Column Group LLC
The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Finance |
| Glaxo, Inc. | |
Circle Pharma, Inc.
Circle Pharma, Inc. BiotechnologyHealth Technology Circle Pharma, Inc. provides biotechnology services. The company was founded by Matthew P. Jacobson and Scott Lokey in June 2014 and is headquartered in San Francisco, CA. | Health Technology |
Nura Bio, Inc.
Nura Bio, Inc. Pharmaceuticals: MajorHealth Technology Nura Bio, Inc. develops neuroprotective drugs. The company is headquartered in South San Francisco, CA. | Health Technology |
Atavistik Bio, Inc.
Atavistik Bio, Inc. BiotechnologyHealth Technology Atavistik Bio, Inc. is a pre-clinical stage biotechnology company located in an undisclosed location. The American company is pioneering a synthetic, scalable approach to identify and harness highly conserved protein-metabolite interactions to revolutionize small molecule drug discovery. The company's advanced data analytics and AI platforms leverage structure-based drug design to engineer novel, highly specific small molecule drugs to activate, inhibit or stabilize targets. The company is led by an experienced management team and advisors, plus a robust investment syndicate, and is positioned to deliver transformational science to ultimately improve patient care. Atavistik Bio was founded by prominent scientists who are considered among the leading authorities in cell biology, cancer cell biology and cell metabolism. Bryan E Stuart has been the CEO of the company since 2023. | Health Technology |
| VHL Alliance |
- Stock Market
- Insiders
- John A. Josey
